Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the release of a new genetic test, lysoSEEK™, which is focused on early identification of genes associated with potentially treatable lysosomal storage disorders.

EMPATHY-P showed that Prolaris provides valuable clinical information that can help physicians improve healthcare and outcomes for their patients with early prostate cancer,” said Colin Hayward, M.D., European medical director, Myriad. “There is no one-size-fits-all treatment approach in prostate cancer. Prolaris provides objective genetic information to help clinicians tailor treatment plans based on patients’ individual risk profiles.

A whole-genome sequencing study of families with multiple children with autism spectrum disorder has found that siblings often don’t share ASD-related mutations, the researchers say in Nature Genetics.

Myriad Genetics, in collaboration with SciencewerkeDX organised a series of talks in Jan 2015 to raise awareness of hereditary cancer.

Our speaker, Karen Copeland is the director of International Medical Affairs, Myriad Genetics GmbH and also a certified genetic counsellor.

Myriad Genetics today announced it has received approval from the US Food and Drug Administration for BRACAnalysis CDx™ as a companion diagnostic for AstraZeneca’s Lynparza™ (olaparib), a new drug for advanced ovarian cancer associated with BRCA genes.